Literature DB >> 10071231

P16/MTS1 and pRB expression in endometrial carcinomas.

K Milde-Langosch1, L Riethdorf, A M Bamberger, T Löning.   

Abstract

p16MTS1/CDKN1 and the retinoblastoma protein Rb are both involved in negative regulation of G1/S progression in the mammalian cell cycle. Inactivation of one of these tumour suppressor genes is involved in many malignant tumours, and in some studies a negative correlation of p16 and Rb expression has been found. In order to study this interaction in endometrial carcinogenesis, we investigated 36 endometrial carcinomas, 11 cases of hyperplasia, 23 normal endometrial samples, and two uterine carcinoma cell lines by immunohistochemistry or RT-PCR. Rb was expressed in normal endometrial epithelium, hyperplasia, cell lines, and most carcinomas; negative immunostaining was only detected in 1 of 36 tumours. In contrast, p16 expression was weak in normal endometrium and increased in most cases of hyperplasia, but negative or minimally positive in 74% of the carcinomas and the Hec1B adenocarcinoma cell line, and there was no significant association with Rb immunostaining. Strikingly high p16 expression was found in foci of squamous metaplasia within hyperplastic or carcinomatous tissue. Deletion and mutation analysis of the p16 gene was performed in DNA from microdissected tumour samples and cell lines. No p16 deletion was found, and mutations were detected in only one tumour sample and Skut1B uterine mixed mesodermal tumour cells. Our data indicate that in spite of low or absent p16 expression, genetic alterations of the p16 and Rb tumour suppressor genes are rare in endometrial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071231     DOI: 10.1007/s004280050300

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

1.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

2.  Induction of the tumor-suppressor p16(INK4a) within regenerative epithelial crypts in ulcerative colitis.

Authors:  Emma E Furth; Karen S Gustafson; Charlotte Y Dai; Steven L Gibson; Paul Menard-Katcher; Tina Chen; Jim Koh; Greg H Enders
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma.

Authors:  Zhuo-ying Hu; Liang-dan Tang; Qin Zhou; Lin Xiao; Yi Cao
Journal:  Tumour Biol       Date:  2015-01-17

4.  Biomarkers in endometrial cancer: Possible clinical applications (Review).

Authors:  Kouji Banno; Iori Kisu; Megumi Yanokura; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Oncol Lett       Date:  2012-03-26       Impact factor: 2.967

5.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

6.  Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.

Authors:  Juliane Briese; Heinrich M Schulte; Maria Sajin; Christoph Bamberger; Katja Redlin; Karin Milde-Langosch; Thomas Löning; Ana-Maria Bamberger
Journal:  Virchows Arch       Date:  2008-04-16       Impact factor: 4.064

Review 7.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

8.  Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.

Authors:  Shinji Mizuarai; Takumitsu Machida; Tsutomu Kobayashi; Hideya Komatani; Hiraku Itadani; Hidehito Kotani
Journal:  Mol Cancer       Date:  2011-03-29       Impact factor: 27.401

9.  The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.

Authors:  H Tsuda; K Yamamoto; T Inoue; I Uchiyama; N Umesaki
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.

Authors:  Chiew-Loon Koo; Lai-Fong Kok; Ming-Yung Lee; Tina S Wu; Ya-Wen Cheng; Jeng-Dong Hsu; Alexandra Ruan; Kuan-Chong Chao; Chih-Ping Han
Journal:  J Transl Med       Date:  2009-04-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.